IDEAYA Biosciences, Inc. IDYA IDE397 — External Clinical Development Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s ide397 — external clinical development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s IDE397 — external clinical development expenses?
- IDEAYA Biosciences, Inc. (IDYA) reported IDE397 — external clinical development expenses of $3.52M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s IDE397 — external clinical development expenses changed year-over-year?
- IDEAYA Biosciences, Inc.'s IDE397 — external clinical development expenses decreased by 6.0% year-over-year, from $3.74M to $3.52M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s IDE397 — external clinical development expenses?
- Over 3 years (2022 to 2025), IDEAYA Biosciences, Inc.'s IDE397 — external clinical development expenses has grown at a 15.9% compound annual growth rate (CAGR), from $9.43M to $14.66M.
- What does IDE397 — external clinical development expenses mean?
- This metric represents the total third-party costs incurred for the clinical advancement of a specific oncology drug candidate, including expenses related to clinical trial sites, contract research organizations, and patient enrollment. It serves as a key indicator of the capital intensity and development velocity associated with a particular therapeutic pipeline asset. Monitoring these expenditures helps investors assess the company's resource allocation toward high-potential precision medicine programs.